Plain-English translation of NCT06656702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study is testing whether , a naturally occurring psychedelic compound, can help people with ALS (amyotrophic lateral sclerosis) who are experiencing depression. The study will track how the medication affects mood, quality of life, and overall well-being. Researchers want to learn if this treatment is safe and feasible for this patient group.
Many people diagnosed with ALS struggle with depression, which can make an already difficult disease even harder to manage. This medication has shown promise in other research for helping with depression and existential distress, so researchers want to see if it could be helpful and safe for people with ALS.
You likely qualify if…
You likely don't qualify if…
You would participate in an 8-week treatment program that includes two medication sessions—one in week 4 and one in week 6. You'll take tablets by mouth under medical supervision, and the research team will monitor your depression, mood, quality of life, and functional abilities. After your final session, you'll have follow-up check-ins at 1, 3, and 6 months to see how you're doing.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Johns Hopkins University
Collaborators
United States Department of Defense, Congressionally Directed Medical Research Programs
Enrollment target
~24 participants
Started
April 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Betsy Mosmiller
Johns Hopkins University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.